Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Total Liabilities
Everything the company owes to creditors and other parties.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 17.6% from a year ago
Total liabilities stood at $28.62M at the end of Q1 FY2026, down 17.6% from a year earlier and down 7.1% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.
Context
- Total liabilities amounted to 21.5% of total assets at the end of Q1 FY2026, up 1.8 pp from a year earlier.
- Total liabilities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -17.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 30.8M USD
- Year-over-year change
- -21.7%
- 4-year CAGR
- -12.2%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.8M | -21.7% |
| FY2024 | 2024-12-31 | 39.36M | -5.9% |
| FY2023 | 2023-12-31 | 41.83M | +3.1% |
| FY2022 | 2022-12-31 | 40.56M | -21.7% |
| FY2021 | 2021-12-31 | 51.78M | — |
Total Liabilities vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -17.6% is the 10th highest of 11, against a peer median of +5.4%.
- Total liabilities amounts to 21.5% of total assets for BDTX, versus a peer median of 31.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $8.29B USD | +93713.8% | +2.6% | 3.9% | |
| Mar 2026 | $298.58M USD | -6.8% | -8.8% | 134.4% | |
| Dec 2025 | €277.91M EUR | +23.2% | +57.9% | 111.7% | |
| Mar 2026 | $198.12M USD | -13.7% | +53.9% | 63.0% | |
| Mar 2026 | $53.56M USD | -7.6% | +17.2% | 27.0% | |
| Mar 2026 | $46.98M USD | -16.8% | -10.0% | 31.5% | |
| Mar 2026 | $34.15M USD | -34.7% | +5.9% | 47.5% | |
| Mar 2026 | $31.57M USD | +98.4% | -9.0% | 31.6% | |
| Mar 2026 | $28.88M USD | +17.6% | -12.7% | 21.4% | |
| Mar 2026 | $28.62M USD | -17.6% | -8.8% | 21.5% | |
| Mar 2026 | $11.6M USD | +83.1% | -38.2% | 11.8% | |
| Peer median (excluding BDTX) | — | +5.4% | -3.1% | 31.6% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 65.8M | 34.32M | 56.22M | 36.44M | 20.99M |
| Short-term Investments | 143.99M | 88.49M | 75.18M | 62.14M | 107.66M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 4.9M | 2.63M | 2.6M | 3.79M |
| Total Current Assets | 215.7M | 127.71M | 134.03M | 101.18M | 132.44M |
| Property, Plant & Equipment (Net) | 30.74M | 27.38M | 23.71M | 20.4M | 9.67M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 829K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.24M | 1.17M | 823K | 1.07M | 73K |
| Total Non-current Assets | 31.98M | 28.55M | 24.53M | 21.46M | 10.57M |
| Total Assets | 247.68M | 156.26M | 158.57M | 122.64M | 143.01M |
| Account Payables | 4.11M | 1.88M | 2.32M | 4.01M | 579K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 23.64M | 15.26M | 19.65M | 20.57M | 15.73M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 28.14M | 25.3M | 22.19M | 18.78M | 15.07M |
| Total Liabilities | 51.78M | 40.56M | 41.83M | 39.36M | 30.8M |
| Common Stock | 5K | 5K | 7K | 7K | 8K |
| Retained Earnings | (243.82M) | (334.99M) | (417.43M) | (487.11M) | (464.74M) |
| Accumulated OCI | (414K) | (1.82M) | (27K) | 24K | 101K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 195.9M | 115.7M | 116.74M | 83.29M | 112.21M |
| Total Debt | 28.46M | 28.14M | 25.3M | 22.19M | 18.78M |
| Net Debt | (37.34M) | (6.18M) | (30.92M) | (14.25M) | (2.21M) |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.